FGF21 and metabolic dysfunction-associated steatotic liver disease: Our current results also showed that Fgf21 was significantly upregulated in the DIO + DHA group, suggesting that the beneficial effects of this n-3 PUFA on age and obesity-related MASLD could be mediated, at least in part, by Fgf21 upregulation.